Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dizal Pharmaceutical CoSHSE:688192 -4.14%27 PS Ratio is 29.75 as of Jul. 23, 2026, which is 72% below its 10-year median of 105.44. GuruFocus rates SHSE:688192 with a GF Score™ of 27/100 and a GF Value™ of ¥138.05 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 952 Drug Manufacturers companies, Dizal Pharmaceutical Co ranks worse than 95.27% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Dizal Pharmaceutical Co's share price is ¥58.34.
Dizal Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1.96. Hence, Dizal Pharmaceutical Co's PS Ratio for today is 29.75.
The historical rank and industry rank for Dizal Pharmaceutical Co's PS Ratio or its related term are showing as below:
SHSE:688192'
s PS Ratio Range Over the Past 10 Years
Min: 18.61 Med: 105.44 Max: 5400
Current: 29.74
During the past 8 years, Dizal Pharmaceutical Co's highest PS Ratio was 5400.00. The lowest was 18.61. And the median was 105.44.
SHSE:688192's PS Ratio is ranked worse than 95.27% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.295
vs SHSE:688192: 29.74
During the past 8 years, Dizal Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 210.50% per year. The lowest was 42.80% per year. And the median was 126.65% per year.
Back to Basics: PS Ratio
Dizal Pharmaceutical Co (SHSE:688192) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dizal Pharmaceutical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dizal Pharmaceutical Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dizal Pharmaceutical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Dizal Pharmaceutical Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Dizal Pharmaceutical Co's Share Price of today is ¥58.34. Dizal Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.96.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Dizal Pharmaceutical Co (SHSE:688192) has a PS Ratio of 29.75 as of Jul. 23, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Dizal Pharmaceutical Co and its competitors. This is 72% below median its historical median of 105.44. Over the past decade, Dizal Pharmaceutical Co's PS Ratio has ranged from 18.61 to 5,400.00. According to the industry distribution chart, Dizal Pharmaceutical Co ranks #907 out of 952 companies in the Drug Manufacturers industry, placing it in the top 95.3%.
Is Dizal Pharmaceutical Co's PS Ratio too high?
Dizal Pharmaceutical Co's current PS Ratio of 29.75 is 72% below median its 10-year median of 105.44. Over the past 10 years, this metric has ranged from a low of 18.61 to a high of 5,400.00. The Drug Manufacturers industry median PS Ratio is 2.30. Dizal Pharmaceutical Co's value of 29.75 is 1196.3% above this industry median. Based on the distribution chart, Dizal Pharmaceutical Co ranks #907 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dizal Pharmaceutical Co has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dizal Pharmaceutical Co's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dizal Pharmaceutical Co ranks #907 out of 952 companies for PS Ratio. This places Dizal Pharmaceutical Co in the lower half of its industry. The industry median PS Ratio is 2.30. Dizal Pharmaceutical Co's value of 29.75 is 1196.3% above this benchmark. Historically, Dizal Pharmaceutical Co's own PS Ratio has ranged from 18.61 to 5,400.00 over the past decade. While the company's 10-year median is 105.44 vs. the industry median of 2.30, Dizal Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dizal Pharmaceutical Co's current PS Ratio of 29.75 is 1196.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Dizal Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dizal Pharmaceutical Co's current PS Ratio is 29.75, which is 72% below median its own 10-year median of 105.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dizal Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Dizal Pharmaceutical Co (SHSE:688192) is currently considered Possible Value Trap. The stock's GF Value™ is ¥138.05, compared to a current price of ¥58.34 — trading 57.7% below its estimated fair value. The current PS Ratio is 29.75, which is 72% below median its 10-year median of 105.44 and 1196.3% above the Drug Manufacturers industry median of 2.30. Dizal Pharmaceutical Co's overall GF Score™ is 27/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Dizal Pharmaceutical Co (SHSE:688192), the current PS Ratio is 29.75 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dizal Pharmaceutical Co (SHSE:688192) Overvalued in 2026?
Based on GuruFocus' analysis, Dizal Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥58.34 is trading 57.7% below its estimated GF Value™ of ¥138.05.
GuruFocus considers Dizal Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for SHSE:688192:
PS Ratio: 29.75 (72% below median its 10-year median of 105.44)
GF Value™: ¥138.05 vs. price of ¥58.34 (57.7% below fair value)
Industry Position: 1196.3% above the Drug Manufacturers median (#907 of 952)
No single metric tells the full story. See the SHSE:688192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dizal Pharmaceutical Co Ltd, formerly Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development, production and sales of innovative drugs.
27GF Score
Get the complete analysis for SHSE:688192
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688192 has been successfully added to your 
